European authorities will this week base a decision on whether to approve AstraZeneca's COVID-19 vaccine on available data, German Health Minister Jens Spahn said, declining to comment on media reports it is not so effective for the elderly.
Global Cases Top 100 Million; N.J. May Relax Curbs: Virus Update Bloomberg 1/26/2021 Bloomberg News
(Bloomberg) Global coronavirus cases surpassed 100 million, according to data compiled by Johns Hopkins University, marking another grim milestone in the pandemic.
New York City said it would miss its goal of administering 1 million vaccine shots by the end of January, and Mayor Bill de Blasio appealed to the Biden administration for more doses.
Pfizer Inc. will be able to supply the U.S. with 200 million Covid-19 vaccine doses two months sooner than previously forecast, according to its top executive. European Medicines Agency Executive Director Emer Cooke signaled Pfizer is gearing up to increase deliveries to EU countries.
Global Cases Top 100 Million; N.J. May Relax Curbs: Virus Update Bloomberg 1/26/2021 Bloomberg News
(Bloomberg) Global coronavirus cases surpassed 100 million, according to data compiled by Johns Hopkins University, marking another grim milestone in the pandemic.
New York City said it would miss its goal of administering 1 million vaccine shots by the end of January, and Mayor Bill de Blasio appealed to the Biden administration for more doses.
Pfizer Inc. will be able to supply the U.S. with 200 million Covid-19 vaccine doses two months sooner than previously forecast, according to its top executive. European Medicines Agency Executive Director Emer Cooke signaled Pfizer is gearing up to increase deliveries to EU countries.
AstraZeneca rejects ‘incorrect’ reports on Covid jab efficacy in elderly
350
BERLIN, Jan 26, 2021 (BSS/AFP) – Pharma giant AstraZeneca has defended the efficacy of its Covid-19 vaccine after media reports said the German government had doubts about its effectiveness among those over 65.
The Handelsblatt economic daily reported Monday that Berlin had estimated the efficacy of the jab among over-65s was just eight percent, citing sources.
Bild also said that Berlin did not expect the vaccine developed with Oxford University and set to get the green light from the EU this week would receive a licence for use in the elderly, presenting a significant challenge to rollout plans in many countries.